Science Explorer Back to mapMap
Discussion
Researcher · Ulsan College · South Korea

S. Kim

S. Kim publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Epidemiology, on topics such as Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies and Gastric Cancer Management and Outcomes.

ORCID 0009-0004-8746-7486 OpenAlex
World rank
#4,090,079
of 7,710,434 ranked researchers
Rank in South Korea
#67,526
of 162,609
Works
46
Citations
244
Citations per work
5.3
h-index
6
i10-index 5Top 78% in Pulmonary and Respiratory Medicine
S. Kim

What does S. Kim research?

S. Kim's work is mostly in Medicine (59%), Biochemistry, Genetics and Molecular Biology (7%).

Health Sciences: 27 works · 58.7% of their workMedicine: 27 works · 58.7% of their workPulmonary and Respiratory Medicine: 14 works · 29.8% of their workOncology: 8 works · 18.2% of their workEpidemiology: 3 works · 6.6% of their workHematology: 2 works · 4.1% of their workEverything else: 16 works · 34.7% of their workLife Sciences: 3 works · 6.6% of their workBiochemistry, Genetics and Molecular Biology: 3 works · 6.6% of their workCancer Research: 2 works · 3.3% of their workMolecular Biology: 2 works · 3.3% of their workTHEIR WORKS. Kim46works
Life Sciences7%Health Sciences59%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine2758.7%
  2. Everything else1634.7%
    1. Biochemistry, Genetics and Molecular Biology36.6%
  1. 1Pulmonary and Respiratory Medicine30% of their works
  2. 2Oncology18% of their works
  3. 3Epidemiology7% of their works
  4. 4Hematology4% of their works
  5. 5Molecular Biology3% of their works
  6. 6Cancer Research3% of their works

Research topics

Which keywords describe S. Kim's research?

The keywords of their largest research topics: Clinical Trials, Targeted Therapy, Chemotherapy, ALK Inhibitors, EGFR Mutations, Adjuvant Therapy, Cetuximab and Congenital Heart Disease.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 22 words, with their numbers
  1. Clinical Trials262 topics
  2. Targeted Therapy262 topics
  3. Chemotherapy244 topics
  4. ALK Inhibitors211 topic
  5. EGFR Mutations211 topic
  6. Adjuvant Therapy112 topics
  7. Cetuximab81 topic
  8. Congenital Heart Disease82 topics
  9. KRAS Mutations81 topic
  10. Prognostic Factors82 topics
  11. Endoscopic Resection71 topic
  12. Gastric Cancer71 topic
  13. Cardiac Surgery51 topic
  14. Genomic Profiles51 topic
  15. Pulmonary Valve Replacement51 topic
  16. Small-Cell Lung Cancer51 topic
  17. CT Screening41 topic
  18. Lung Cancer41 topic
  19. Cardiovascular Diseases31 topic
  20. Chronic Lymphocytic Leukemia31 topic
  21. Genomic Aberrations31 topic
  22. Pregnancy31 topic

Where does S. Kim work?

S. Kim's main affiliation in the publication record is Ulsan College, South Korea.

How many publications and citations does S. Kim have?

OpenAlex counts 46 works and 244 citations for S. Kim, an h-index of 6, ranking #4,090,079 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Other researchers named S. Kim

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about S. Kim. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.